Vistagen Therapeutics Financials - Benzinga

Vistagen Therapeutics Inc

VTGNNASDAQ

Trade with Public

Trade with Public

$0.2730

-0.022-7.46%

近くで: Sep 25, 5:00 PM EST

$0.2620

-0.011-4.03%

時間外: 7:57 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Vistagen Therapeutics Financials

Vistagen Therapeutics (VTGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share

Benzinga Newsdesk

PRO
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per

Benzinga Newsdesk

Vistagen Therapeutics Earnings Report: Q3 Overview

Benzinga Insights

PRO
VistaGen Therapeutics Q3 EPS $(0.45) Misses $(0.44) Estimate, Sales $303.000K Miss $366.000K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.44) by 2.74 percent. This is a 2.17 percent increase over losses of $(0.46) per share

Benzinga Newsdesk

Earnings Scheduled For February 12, 2026

Benzinga Insights

Crude Oil Rises Over 1%; General Mills Earnings Top Views

Avi Kapoor

© 2026 Benzinga | All Rights Reserved